Streetbeat News

Products Services

DD

The global human microbiome market is projected to grow from $486 million in 2023 to $2.8 billion by 2030, driven by companies like Dow, DuPont de Nemours, and Enterome. The Gastrointestinal Diseases segment is expected to reach $1.3 billion by 2030 with a CAGR of 28.7%, while the Endocrine & Metabolic Disorders segment will grow at a 23.6% CAGR. The U.S. market was valued at $141.2 million in 2023, and China's market is forecasted to grow at a 27.4% CAGR to $417.6 million by 2030.

Portfolio Pulse from

December 03, 2024 | 4:30 pm

EBAY

eBay's stock has gained 45% year-to-date, driven by an expanding product portfolio. However, challenges such as slow active user growth and intense competition remain.

Portfolio Pulse from

December 03, 2024 | 4:30 pm

NVDA

NVIDIA's stock has surged 180% year-to-date, driven by its dominance in AI and strong financial performance, making it a recommended buy.

Portfolio Pulse from

December 03, 2024 | 4:15 pm

XOVR

ERShares Crossover ETF (XOVR) has announced SpaceX as its top holding, marking its first private equity investment. This move revolutionizes access to private equity for retail investors by blending public and private equities in a single fund.

Portfolio Pulse from

December 03, 2024 | 4:15 pm

NVCR

Novocure's stock surged by 49% after its TTFields therapy met the primary endpoint of overall survival in a late-stage study for treating pancreatic adenocarcinoma.

Portfolio Pulse from

December 03, 2024 | 4:15 pm

EGHT

8x8, Inc. (EGHT) has seen a 38% rise in its stock price over the past month. The company's expanding AI-powered portfolio, strong partner base, and attractive valuation are key factors making it appealing to investors.

Portfolio Pulse from

December 03, 2024 | 4:15 pm

CRM

MRVL

Salesforce (CRM) and Marvell (MRVL) are in focus as they report earnings. Analyst Angelo Zino suggests Marvell has overcome its worst phase and is now poised for growth in AI.

Portfolio Pulse from

December 03, 2024 | 4:00 pm

JANX

Janux Therapeutics' stock surged by 70% following positive Phase 1 trial results for its new prostate cancer treatment.

Portfolio Pulse from

December 03, 2024 | 4:00 pm

BUD

AB InBev has invested $10 million in its Jacksonville brewery, highlighting its commitment to producing high-quality products.

Portfolio Pulse from

December 03, 2024 | 4:00 pm

BMY

Bristol-Myers Squibb Company (BMY) participated in Citi's 2024 Global Healthcare Conference, with CEO Christopher Boerner and CFO David Elkins representing the company.

Portfolio Pulse from

December 03, 2024 | 4:00 pm